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is only available for a subset of the study population, e.g. survey
data of life-style factors. Another example is recursive partitioning
(Seeger et al., 2006), which can be used to reﬁne study variables
(e.g., confounders or outcomes) in a subset of the population that can
then be applied to the entire study population.Thank you for an excellent and comprehensive commentary
(Patrignani and Dovizio, 2016) that highlights the ﬁndings of our
paper (Pottegård et al., 2016) and provides suggestions for the road
forward in pharmacoepidemiologic studies. While “individualized ther-
apy” is somewhat beyond the scope of the current study, utilizing an
epidemiological/population-based analysis, we fully agree that research
integrating clinical, lifestyle, and molecular data is an important step
forward for improving drug therapy. In our opinion, our approach
targeting multiple drug-cancer associations and the applied analyses
can be considered a ﬁrst step towards such integrated studies. However,
the challenge lies in identifying data sources that can provide drug,
clinical, lifestyle and genetic data for a sufﬁciently large population. In
the context of the present study (Pottegård et al., 2016), we used pre-
scription drug data dating back to 1995 (Kildemoes et al., 2011). Long-
term data are necessary in the study of outcomes with long latency
such as cancer (Umar et al., 2012). Importantly, the casemight be differ-
ent for acute events, such as bleeding or cardiovascular events. We
believe that advances in the study of cancer risk associated with
prescription drug use will require innovative methods that make use
of detailed data on a subset of a population in ways that leverage the in-
formation for the analysis of the full population. One example in
pharmacoepidemiology is propensity score calibration (Stürmer et al.,/j.ebiom.2016.03.018, http://
ersity of Southern Denmark, JB
ård).
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